Form 4: Agenus CEO Garo Armen Opts for Stock Salary

Agenus Inc. CEO Garo H. Armen elected to receive 3,778 shares of common stock valued at $4.33 per share as salary for the pay period ending September 5, 2025.

Summary

• Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc., acquired 3,778 shares of Agenus common stock.
• The acquisition was a result of Dr. Armen's request, approved by the Compensation Committee, to receive his salary in stock instead of cash.
• The shares were issued for the pay period ending September 5, 2025, at a price of $4.33 per share, which was the closing price on that date.
• These shares are fully vested upon issuance in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan.
• Following this transaction, Dr. Armen directly owns 274,708 shares and indirectly owns 31,298 shares in IRA accounts and 28,950 shares through the Garo Armen 2020 2 Year AG GRAT and Pixie Partners.

Sentiment

Score: 7

Explanation: The decision by the CEO to take salary in stock is generally viewed as a positive signal, indicating confidence in the company's future and aligning management's interests with shareholders. It's a routine compensation disclosure but carries a positive undertone.

Positives

• Management's decision to take salary in stock demonstrates confidence in the company's future performance and aligns their interests with shareholders.
• The shares are fully vested upon issuance, indicating immediate ownership and commitment.

Future Outlook

No explicit forward-looking statements or guidance are provided beyond the details of the reported transaction.

Management Comments

• At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash.

Industry Context

This transaction reflects a common practice among executives to align their compensation with shareholder interests, particularly in growth-oriented biotechnology companies where stock performance is a key indicator of success.

Comparison to Industry Standards

• Many executives in the biotechnology sector, such as those at Moderna (MRNA) or BioNTech (BNTX), frequently receive a significant portion of their compensation in equity, aligning their financial incentives with the company's stock performance.
• This practice is generally viewed positively as it signals management's confidence in the company's long-term prospects, similar to how executives at companies like Regeneron Pharmaceuticals (REGN) or Amgen (AMGN) often increase their equity holdings.

Related Party Transactions

• Garo H. Armen's salary is paid in stock, representing a transaction between an officer/director and the company.
• Indirect ownership includes shares held by the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, entities where Dr. Armen has a pecuniary interest or investment authority.

Stakeholder Impact

• Shareholders: Potentially positive, as it signals management's confidence and aligns their interests with shareholder value creation.

Key Dates

Recommendation

This Form 4 filing details a routine compensation event where the CEO opted for stock in lieu of cash salary. While this signals management confidence, it is a relatively small transaction in the context of the company's overall market capitalization and does not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Agenus Inc., AGEN, Garo H. Armen, Insider Transaction, Stock Compensation, CEO Salary, Equity Incentive Plan, Form 4, Beneficial Ownership